You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD

  • Authors: Alan S. Brown, MD; Kausik K. Ray, BSc (hons), MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed)
  • CME / ABIM MOC / CE Released: 12/5/2017; Reviewed and Renewed: 12/14/2018
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 12/14/2019
Start Activity


Target Audience and Goal Statement

This activity is intended for cardiologists, PCPs, diabetologists, endocrinologists, nurse practitioners, nurses, and other clinicians interested in managing dyslipidemia.

The goal of this activity is to improve the management of dyslipidemia and clinical interpretation of the most current data in secondary prevention.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the:
    • Latest data on the efficacy and safety of statin therapy in secondary prevention of coronary artery disease (CAD)
    • Value of a team approach in the management of dyslipidemia
  • Have greater competence related to:
    • The ability to tailor lipid-lowering therapy in high-risk patients with dyslipidemia


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator(s)

  • Alan S. Brown, MD

    Clinical Associate Professor; Loyola Stritch School of Medicine; Director, Division of Cardiology Advocate Lutheran General Hospital Chicago, Illinois, United States

    Disclosures

    Disclosure: Alan Brown, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Akcea Therapeutics; Kastle Therapeutics; Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
    Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Kowa Company Ltd.; Regeneron Pharmaceuticals, Inc.; Sanofi

    Dr Brown does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Brown does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Kausik K. Ray, BSc (hons), MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed)

    Professor of Public Health; Honorary Consultant Cardiologist Imperial Centre for Cardiovascular Disease Prevention; Department of Primary Care and Public Health; Imperial College London, London, United Kingdom

    Disclosures

    Disclosure: Kausik K. Ray, BSc (hons), MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed), has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Cerenis Therapeutics; Ionis Pharmaceuticals, Inc.; Lilly; Medco Health Solutions, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
    Served as a speaker or a member of a speakers bureau for: Algorithm Pharmaceutical Manufacturers; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Cipla Ltd.; Kowa Company Ltd.; Pfizer Inc.; Takeda Pharmaceuticals North America, Inc.
    Received grants for clinical research from: Amgen Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi

    Dr Ray does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Ray does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Joy P. Marko, MS, APN-C, CCMEP

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Joy P. Marko, MS, APN-C, CCMEP, has disclosed no relevant financial relationships.

CME Reviewer / Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; HeartWare International, Inc; Medtronic, Inc.; Thoratec Corporation


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

     

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD

Authors: Alan S. Brown, MD; Kausik K. Ray, BSc (hons), MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed)Faculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 12/5/2017; Reviewed and Renewed: 12/14/2018

Valid for credit through: 12/14/2019

processing....

  • Print